Table 5. Biomarker analysis and clinical outcome.
| Patient number | Gender | Age | Histology | Previous gefitinib response | EGFR mutation status | Response to CPT-11 and gefitinib |
|---|---|---|---|---|---|---|
| L1-2 | Male | 54 | Squamous | PD | Wild | PD |
| L2-3 | Female | 55 | Adeno | PD | Wild | PD |
| L3-5 | Female | 75 | Adeno | PR | Wild | SD |
| L4-2 | Female | 57 | Adeno | PR | Wild | NE |
| L5-1 | Female | 58 | Adeno | PR | L858R | SD |
| L5-2 | Male | 63 | Adeno | PR | Wild | PR |
| L5-3 | Male | 75 | Adeno | PD | Wild | PD |
| L5-4 | Male | 64 | Adeno | PR | Deletion | PR |
| L5-9 | Female | 64 | Adeno | PR | Deletion | PR |
| L5-12 | Female | 48 | Adeno | PR | Deletion | PD |
Abbreviations: CPT-11=irinotecan; EGFR=epidermal growth factor receptor; Squamous=squamous cell carcinoma; Adeno=adenocarcinoma; PR=partial response; SD=stable disease; PD=progressive disease; NE=not evaluable; Wild=wild-type; L858R=L858R within exon 21; Deletion=in-frame deletions within exon 19.